mTOR Inhibition Induces EGFR Feedback Activation in Association with Its Resistance to Human Pancreatic Cancer

Pancreatic Adenocarcinoma

(2015) David P. Ryan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Will PI3K pathway inhibitors be effective as single agents in patients with cancer?

(2015) Joan T. Garrett et al.   Oncotarget

Loss of E-cadherin activates EGFR-MEK/ERK signaling, which promotes invasion via the ZEB1/MMP2 axis in non-small cell lung cancer

(2015) Gab-Yong Bae et al.   Oncotarget

mTOR kinase inhibitors as potential cancer therapeutic drugs

(2013) Shi-Yong Sun   CANCER LETTERS

Everolimus in Advanced Pancreatic Neuroendocrine Tumors: The Clinical Experience

(2013) J. C. Yao et al.   CANCER RESEARCH

Pan-Mammalian Target of Rapamycin (mTOR) Inhibitor AZD8055 Primes Rhabdomyosarcoma Cells for ABT-737-induced Apoptosis by Down-regulating Mcl-1 Protein

(2013) Ellen Preuss et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

miR-99b-targeted mTOR induction contributes to irradiation resistance in pancreatic cancer

(2013) Feng Wei et al.   Molecular Cancer

mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1

(2013) A. C. Faber et al.   Cancer Discovery

Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055)

(2012) S. V. Holt et al.   CANCER RESEARCH

Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study

(2012) Hajime Asahina et al.   INVESTIGATIONAL NEW DRUGS

AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity

(2011) Sarat Chandarlapaty et al.   CANCER CELL

Pancreatic cancer

(2011) Audrey Vincent et al.   LANCET

Rapamycin Induces Bad Phosphorylation in Association with Its Resistance to Human Lung Cancer Cells

(2011) Y. Liu et al.   MOLECULAR CANCER THERAPEUTICS

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

(2011) V Serra et al.   ONCOGENE

mTOR Inhibition, the Second Generation: ATP-Competitive mTOR Inhibitor Initiates Unexpected Receptor Tyrosine Kinase-Driven Feedback Loop

(2011) M. Keniry et al.   Cancer Discovery

mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling

(2011) V. S. Rodrik-Outmezguine et al.   Cancer Discovery

Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors’ anticancer efficacy

(2010) Xuerong Wang et al.   CANCER BIOLOGY & THERAPY

Pancreatic Cancer

(2010) Manuel Hidalgo   NEW ENGLAND JOURNAL OF MEDICINE

mTOR Signaling Pathway Is a Target for the Treatment of Colorectal Cancer

(2009) Yan-Jie Zhang et al.   ANNALS OF SURGICAL ONCOLOGY

Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer

(2009) Tetsuya Mitsudomi et al.   FEBS Journal

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

(2009) Carson C. Thoreen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Unravelling the tumor-suppressive functions of FOXO proteins

(2008) Tobias B. Dansen et al.   TRENDS IN CELL BIOLOGY